Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
Intelligent Bio Solutions (INBS) celebrates one year of successful partnership with Mount Anvil, a London-based property developer, implementing their Intelligent Fingerprinting Drug Screening Solution. Mount Anvil, managing approximately 220 employees and 1000 supply chain workers daily, has purchased 5 readers and 1750 cartridges for on-site testing within the first year.
The non-invasive technology analyzes fingerprint sweat samples, delivering results within minutes without requiring specialized facilities. With over 400 customers across 19 countries, INBS plans FDA 510(k) submission in Q4 2024 and US market entry in H1 2025, targeting a drug screening market estimated at $15 billion by 2030.
Intelligent Bio Solutions (INBS) celebra un anno di partnership di successo con Mount Anvil, un sviluppatore immobiliare con sede a Londra, implementando la loro Soluzione di Screening Drug con Fingerprinting Intelligente. Mount Anvil, che gestisce circa 220 dipendenti e 1000 lavoratori della catena di fornitura quotidianamente, ha acquistato 5 lettori e 1750 cartucce per test sul posto nel primo anno.
La tecnologia non invasiva analizza i campioni di sudore delle impronte digitali, fornendo risultati in pochi minuti senza richiedere strutture specializzate. Con oltre 400 clienti in 19 paesi, INBS prevede di presentare la domanda FDA 510(k) nel quarto trimestre del 2024 e di entrare nel mercato statunitense nel primo semestre del 2025, puntando a un mercato di screening drug stimato a 15 miliardi di dollari entro il 2030.
Intelligent Bio Solutions (INBS) celebra un año de exitosa asociación con Mount Anvil, un desarrollador de propiedades con sede en Londres, implementando su Solución de Detección de Drogas con Huellas Dactilares Inteligentes. Mount Anvil, que gestiona aproximadamente 220 empleados y 1000 trabajadores de la cadena de suministro a diario, ha adquirido 5 lectores y 1750 cartuchos para pruebas en el lugar durante el primer año.
La tecnología no invasiva analiza muestras de sudor de huellas dactilares, proporcionando resultados en minutos sin requerir instalaciones especializadas. Con más de 400 clientes en 19 países, INBS planea enviar la solicitud FDA 510(k) en el cuarto trimestre de 2024 y entrar en el mercado estadounidense en el primer semestre de 2025, apuntando a un mercado de detección de drogas que se estima en 15 mil millones de dólares para 2030.
Intelligent Bio Solutions (INBS)는 런던 소재 부동산 개발업체인 Mount Anvil과의 1주년 성공 파트너십을 축하하며, 그들의 지능형 지문 약물 검사 솔루션을 구현했습니다. Mount Anvil은 약 220명의 직원과 하루에 1000명의 공급망 근로자를 관리하며, 첫해에 현장 테스트를 위해 5개의 리더와 1750개의 카트리지를 구매했습니다.
비침습적 기술은 지문 땀 샘플을 분석하여 전문 시설 없이 몇 분 안에 결과를 제공합니다. 19개국에 걸쳐 400명 이상의 고객을 보유한 INBS는 2024년 4분기에 FDA 510(k) 제출을 계획하고 있으며, 2025년 상반기에 미국 시장에 진입할 예정입니다. 2030년까지 150억 달러로 추정되는 약물 검사 시장을 목표로 하고 있습니다.
Intelligent Bio Solutions (INBS) célèbre une année de partenariat réussi avec Mount Anvil, un promoteur immobilier basé à Londres, en mettant en œuvre leur Solution de Dépistage de Drogues par Empreintes Digitales Intelligentes. Mount Anvil, qui gère environ 220 employés et 1000 travailleurs de la chaîne d'approvisionnement quotidiennement, a acquis 5 lecteurs et 1750 cartouches pour des tests sur site au cours de la première année.
La technologie non invasive analyse les échantillons de sueur provenant des empreintes digitales, fournissant des résultats en quelques minutes sans nécessiter d'installations spécialisées. Avec plus de 400 clients dans 19 pays, INBS prévoit de soumettre une demande FDA 510(k) au quatrième trimestre de 2024 et d'entrer sur le marché américain au premier semestre de 2025, ciblant un marché de dépistage des drogues estimé à 15 milliards de dollars d'ici 2030.
Intelligent Bio Solutions (INBS) feiert ein Jahr erfolgreicher Partnerschaft mit Mount Anvil, einem in London ansässigen Immobilienentwickler, und implementiert deren Intelligent Fingerprinting Drug Screening Solution. Mount Anvil, das etwa 220 Mitarbeiter und täglich 1000 Lieferketztenarbeiter beschäftigt, hat im ersten Jahr 5 Lesegeräte und 1750 Kartuschen für Vor-Ort-Tests erworben.
Die nicht-invasive Technologie analysiert Schweißproben von Fingerabdrücken und liefert innerhalb von Minuten Ergebnisse, ohne spezielle Einrichtungen zu benötigen. Mit über 400 Kunden in 19 Ländern plant INBS die Einreichung eines FDA 510(k) Antrags im 4. Quartal 2024 und den Markteintritt in den USA im 1. Halbjahr 2025, mit dem Ziel, einen geschätzten Markt von 15 Milliarden USD für Arzneimittelscreening bis 2030 zu bedienen.
- None.
- None.
Developer Praises Intelligent Bio Solutions’ Innovative Drug Testing Solution for Improving Workplace Safety
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today announced that its customer Mount Anvil, one of London's most respected property developers, has celebrated its one-year anniversary of enhanced workplace safety after integrating INBS’ Intelligent Fingerprinting Drug Screening Solution into its operations.
Brian van Campenhout, Health and Safety Director at Mount Anvil, commented, "Over the past year, Intelligent Bio Solutions' Intelligent Fingerprinting Drug Screening System has exceeded our expectations. Their outstanding service and innovative technology have been integral to maintaining our high safety standards, ensuring our teams operate in a secure and productive environment."
Mount Anvil adopted INBS' drug screening technology to improve workplace safety and efficiency across its construction sites. The company has approximately 220 employees and over 1000 supply chain workers on site daily across its projects. Within 12 months, Mount Anvil have purchased 5 readers and 1750 cartridges for on-site testing. The non-invasive testing method analyzes sweat from a fingerprint sweat sample to detect recent drug use, providing results within minutes without requiring specialized facilities or handling biohazardous materials. On-site testing minimizes downtime and administrative burdens, and immediate results enable swift action to maintain a safe working environment.
"With more than 400 customers in 19 countries, we are pleased to see our customers achieving significant improvements in safety and efficiency with our technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "In safety-critical industries such as real-estate development, effective drug screening solutions that prioritize safety and well-being are essential. Our solution enables businesses to act quickly and responsibly, allowing companies like Mount Anvil to make informed, on-the-spot decisions that protect their teams and sustain productivity across their sites."
The successful integration of INBS’ technology reflects a mutual dedication to innovation and workplace safety between Mount Anvil and INBS.
With FDA 510(k) submission planned in the fourth calendar quarter of this year and entry into the US market planned for the first half of 2025, INBS is capitalizing on the growing drug screening products market, estimated to have a Total Addressable Market of ~
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions to more than 400 customers in 19 countries. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit www.ibs.inc
About Mount Anvil
Mount Anvil exists to Pursue Better, Differently.
In our 30 years, we’ve delivered thousands of outstanding places for Londoners through repeat partnerships. We don’t do shoddy or short-term. If we did, we’d have fizzled out. We’ve weathered recessions while our homes weathered the London drizzle, and all because we’ve gone all-in and created places that people are proud to call home and partnerships that all involved in want to repeat.
As a private company, we’ve been consistently profitable since opening our doors, always thinking long-term. That works for our partners - they come back to us because our vision and values are aligned. They trust us to do what we say we will - create quality, safe and sustainable places that stand the test of time for their residents.
And our ability to do this, all comes back to people and culture – while we’ve evolved over the years, our core values have stayed constant. Our team of owner-managers operate in an environment of freedom, responsibility and learning, each Pursuing Better, Differently.
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
___________________
1 Drug Screening - Global Strategic Business Report, Research and Markets
FAQ
What results has Mount Anvil achieved using INBS's drug screening solution in 2024?
When is INBS planning to enter the US market with their drug screening solution?
How many customers does INBS currently serve with their drug screening technology?
What is the projected market size for drug screening products by 2030?
